SAN FRANCISCO – The nexus of clinical development, regulation and capital was the focus of a panel convened Tuesday at the 30th annual J.P. Morgan Healthcare Conference to discuss a biomedical industry CEO survey conducted by the nonprofit California Healthcare Initiative (CHI), the Northern California life science association BayBio and the pharmaceutical, medical device and life sciences industry group at PricewaterhouseCoopers (PwC).